MABCURE N.V. Signs Research Agreement With AZ Sint Lucas Hospital, Brugge, Belgium, to Conduct Preclinical Research on its Monoclonal Antibodies (Mabs) against Different Cancers

Research Intended to Broaden the Utility of MabCure`s Mabs for Cancer Diagnosis
in Tissue Specimen
HASSELT, Belgium--(Business Wire)--
MabCure N.V., a subsidiary of MabCure Inc. (OTC BB: MBCI), a biotech company
that has developed a series of highly specific monoclonal antibodies (Mabs) to
combat various types of cancers, has signed a research agreement with AZ Sint
Lucas Hospital, Brugge, Belgium. AZ Sint Lucas Hospital will conduct preclinical
research intended to broaden the utility of MabCure`s monoclonal antibodies for
those circumstances where there is a need to diagnose cancer in tissue specimen.
At present, the Company`s Mabs for the diagnosis of ovarian cancer, prostate
cancer and colorectal cancer, for example, are aimed at diagnosing early stage
disease in physiological samples such as urine and serum.

Dr. Amnon Gonenne, CEO of MabCure Inc commented, "If this preclinical research
works, it would open a door for us to diagnose everything that goes through
surgery. This would include, for example, all of the at-risk melanoma patient
population that routinely has moles removed prophylactically. The resection is
arbitrary and there is currently no method to determine if the removed moles
harbor early stage melanoma or not. This is critically important since melanoma
is a highly lethal disease. MabCure`s Mabs may provide a definitive diagnosis of
early stage melanoma in these tissue specimens thereby allowing effective
treatment of the patient. An analogous situation exists in colonoscopy where it
is difficult to provide definitive diagnosis of early colon cancer in the
resected polyps. This approach could be extended to other organs."

Dr. Gonnene continued, "Currently, we address multibillion-dollar opportunities
with the specimens we know our Mabs are effective against. This new opportunity
would allow us to cast an even wider net and we are very excited about the
possibility of helping these patients."

Studies have already begun at AZ Sint Lucas Hospital, and all scientific results
will remain a property of MabCure.

About AZ Sint Lucas Hospital

The Saint Lucas General Hospital in Bruges is an independent hospital with
emphasis on advanced patient care, active clinical research and participation in
multi-center clinical trials.

About MabCure Inc.

MabCure is a biotechnology company whose vision is to change the perception of
cancer as being a largely incurable disease. MabCure owns proprietary technology
for the creation of unique and highly specific monoclonal antibodies (MAbs),
which will be developed as diagnostic tools, imaging agents, and drugs to treat
lethal cancers. MabCure initial goal is to develop its novel MAbs as diagnostic
tools for the detection of Ovarian and Prostate cancers at an early stage, when
these diseases are still localized and highly curable. For further information
visit the Company`s website www.mabcure.com.

Safe Harbor Statement

This news release contains "forward-looking statements". Statements in this news
release which are not purely historical are forward-looking statements and
include any statements regarding beliefs, plans, expectations or intentions
regarding the future. Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors include, among
others, the change of business focus of the management of the Company or the
University and the inability of the Company or the University to pursue its
current objectives. These forward-looking statements are made as of the date of
this news release and the Company or the University assume no obligation to
update the forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking statements.

MabCure Inc.
Dr. Amnon Gonenne, President and CEO
amnon.gonenne@mabcure.com
or
The Investor Relations Group
Public Relations
Laura Colontrelle, 212-825-3210
lcolontrelle@investorrelationsgroup.com
or
Investor Relations
James Carbonara
jcarbonara@investorrelationsgroup.com

Copyright Business Wire 2009